Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 14/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624661 | 0.90 | JAK2 (0.44) | NPY2RCA2CA9TRPV1MEN1 | |
| SCHEMBL17624496 | 0.87 | RAF1 (0.41) | NPY2RCA2CA9TRPV1MEN1 | |
| SCHEMBL17618778 | 0.86 | MAPT (0.41) | NPY2RCA2CA9TRPV1MEN1 | |
| SCHEMBL19706242 | 0.85 | FLT3 (0.39) | FLT3CHEK1MAP3K7KITRPS6KB1 | |
| SCHEMBL17618783 | 0.83 | MEN1 (0.47) | KITTRPV1MEN1ALDH1A1KMT2A | |
| SCHEMBL17618348 | 0.81 | IDH2 (0.45) | CA2CA9TRPV1MEN1ALDH1A1 | |
| SCHEMBL16250003 | 0.80 | CA2 (0.42) | NPY2RCA2CA9MEN1ALDH1A1 | |
| SCHEMBL17618820 | 0.80 | MEN1 (0.43) | NPY2RTRPV1MEN1ALDH1A1KMT2A | |
| SCHEMBL17618817 | 0.80 | CA2 (0.41) | NPY2RCA2CA9TRPV1MEN1 | |
| SCHEMBL17618796 | 0.80 | MEN1 (0.45) | TRPV1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FLT3 319/4885CHEK1 918/4885MAP3K7 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.